

NEWSLETTER SSG XXII

Dear investigators and research coordinators/nurses in SSG XXII,

Mid-term enrollment of 150 out of the planned 300 was achieved at February 21, 2020 and this was done at Vall d'Hebron in Barcelona by PI Dr. Claudia Valverde and her team! Warm congratulations from SSG! Thus, the promised stage prize for this achievement goes to Dr Valverde and this will be a lunch with SSG next time you happen to pass by Lund in Southern Sweden – welcome! :-)



Dr. Claudia Valverde


Hospital Vall d'Hebron, Spain


During the first quarter of the year 13 new patients have been enrolled up to a total of 158 patients, which is very good considering the present covid-19 pandemia. We will especially congratulate Manchester, UK, and Umeå, Sweden, for their first patients! We also note a dramatic rise in The Netherlands during the period – from 7 to 10 patients - +42%! With 14 new patients per quarter the rest of the year we would reach 200 at the year shift – let us try!

As usual you will find the enrolment status per country below and the sites with more than five enrolled patients so far.

During the period we have had two more SAE-reports, both in arm A (with imatinib): one British patient with an infection with fever but without any increased inflammatory parameters or neutropenia who was hospitalized a few days, and one Swedish patient who had diabetes and as a consequence a necrotic toe amputated. None of them was assessed as related to the study drug.

Enrolment status





Covid-19 pandemia

As you hopefully noticed, an extra Newsletter was issued recently regarding potential necessary exceptions. Please, follow the instructions, and turn to us for any questions. We remind here that the two most important things for the trial are; a) that CT scans are made according to the schedule as far as possible, and b) that it is really important not to miss potential new patients because of the general situation – remember that the enrolment window is 3 months!

An important exception from the trial management rules, not mentioned in the recent Extra Newsletter, is that monitoring visits may be postponed, and if needed substituted with phone calls for more urgent needs.

Questions

If you have any questions on the trial protocol, e.g., issues on eligibility, laboratory research sampling, side effects etc. – please ask:

- Your national coordinator or
- The SSG secretariat directly, <u>Eva-Mari.Olofsson@med.lu.se</u> (with email cc to your national coordinator).

Suggestions

Do you have any ideas about what may be included in these Newsletters, please contact the SSG secretariat!

Next Newsletter (No 2/2020) will be sent out in the beginning of July 2020!

For the SSG secretariat

Mikael Eriksson

We wish you a wonderful spring!



You are always welcome to contact us:

Eva-Mari Olofsson, <u>Eva-Mari.Olofsson@med.lu.se</u> Administrative coordinator, SSG

Mikael Eriksson, <u>Mikael.Eriksson@med.lu.se</u> Trial physician

Jeanette Ceberg, <u>Jeanette.Ceberg@croak.se</u> Trial coordinating assistant

SSG secretariat

Eva-Mari Olofsson Administrative coordinator Phone: +46 (0)768 871 408 Webb: <u>www.ssg-org.net</u>

Visit address

Lund University Barngatan 4, Kamprad 5th floor SE-221 85 Lund Sweden

Postal address

Lund University Department of Oncology & Pathology (SSG) Barngatan 4 SE-221 85 Lund Sweden

Invoicing address

Click on the link for more information at https://lunduniversity.lu.se/about/contact-us/supplier-entrance.